Search Within

David Henry Aggen

Formats
  1. Meeting Abstract (45)
  2. Journal Article (10)
  3. Editorial (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (60)
  2. Genitourinary Oncology Service (60)
  3. Hematologic Malignancies, Division of (60)
  4. Solid Tumor Oncology Division (60)
  5. Weinberg Fellows (42)
  6. Graduate Medical Education (38)

More Groups

People
  1. Jonathan Rosenberg (31)
  2. Gopakumar Iyer (29)
  3. Dean Bajorin (26)
  4. Samuel Funt (26)
  5. Min Yuen Teo (25)
  6. Chung-Han Lee (22)

More People

Years
  1. 2025 (9)
  2. 2024 (17)
  3. 2023 (12)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (4)
  3. Cancer Research (3)
  4. European Urology (3)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. American Association for Cancer Research (7)
  3. Biomed Central Ltd (3)
  4. Elsevier Science, Inc. (3)
  5. Elsevier Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance
    Editorial

    Aggen, D. H.; Chu, C. E.; Rosenberg, J. E.
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Katims, A. B.; Lenis, A. T.; Shah, R. H.; Chu, C. E.; Ratna, N.; Regazzi, A. M.; Pietzak, E. J.; Aggen, D. H.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC)
    Meeting Abstract

    Teo, M. Y.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Donahue, T. F.; Goh, A. C.; Cha, E. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer
    Meeting Abstract

    Aggen, D. H.; Hong, D. S.; Clarke, J. M.; Asch, A. S.; Calvo, E.; Zugazagoitia, J.; Butler, M. O.; Moreno, V.; Cervantes, A.; Van Tine, B. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma
    Meeting Abstract

    Aggen, D.; McKean, M.; Lakhani, N.; Bashir, B.; Hoffman-Censits, J.; Alhalabi, O.; Guancial, E.; Bowman, I.; Tan, A.; Lingaraj, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced/metastatic urothelial cancer
    Meeting Abstract

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Chen, Z.; Lattanzi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save